4-demethoxydaunorubicin has sufficient antileukemic activity in both acute lymphocytic leukemia and acute nonlymphocytic leukemia to warrant a prospective comparison , in combination regimens , against the conventional anthracyclines , daunorubicin and/or doxorubicin .
C0023467
acute nonlymphocytic leukemia
C0013089
doxorubicin